TRIM33 and interstitial lung disease: Autoantibody specificities correlate with clinical features, such as the associations between anti-TIF1γ antibodies and high malignancy risk, and anti-melanoma differentiation-associated gene 5 (MDA5) antibodies and rapidly progressive interstitial lung disease (ILD) (3, 4).